Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 743

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 7
Chunk 743
---
 Omnibus Plan, and any shares of common stock issued or cash paid under an award, will be subject to recoupment
our Compensation Recovery Policy (as described below), or any recoupment or similar requirement otherwise made applicable by law, regulation
or listing standards to us, or that may be provided for in any cash or equity award granted by us.

79

Compensation
of Directors

The
following table sets forth all compensation paid to our Board members during the year ended December 31, 2024:

    Name 
    Fees
    Earned or Paid in Cash ($)  
    Stock
    Awards ($)  
    Option
    Awards ($) (1)  
    Non-Equity
    Incentive Plan Compensation ($)  
    Change
    in Pension Value and Nonqualified Deferred Compensation Earnings ($)  
    All
    Other Compensation ($)  
    Total
    ($) 
  
    Matthew
    Whalen 
     -  
         -  
     16,525  
                 -  
             -  
             -  
     - 
  
    Mathew
    Paul Del Giudice 
     -  
     -  
     69,775  
     -  
     -  
     -  
     69,775 
  
    Denil
    Shekhat 
     -  
     -  
     117,400  
     -  
     -  
     -  
     117,400 
  
    Edward
    MacPherson 
     -  
     -  
     69,775  
     -  
     -  
     -  
     69,775 
  
    Dr.
    Christopher Chapman 
     24,121  
     -  
     -  
     -  
     -  
     -  
     - 

    (1)
    The
    reported amounts represent the aggregate grant date fair value of the awards computed in accordance with Financial Accounting Standards
    Board Account Standards Codification Topic 718, Stock Compensation, as modified or supplemented, or FASB ASC Topic 718. The assumptions
    used in calculating the grant date fair value of the stock options reported in this column are set forth in Note 8 to our Consolid